Inquiry Basket
| Catalog | Product Name | CAS Number |
|---|---|---|
| BADC-00855 | SuO-Glu-Val-Cit-PAB-MMAE | 1895916-24-1 |
| SuO-Glu-Val-Cit-PAB-MMAE consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-00856 | MMAE-SMCC | 2021179-11-1 |
| MMAE-SMCC is a drug-linker conjugate for ADC. MMAE-SMCC is composed of a potent mitotic and a tubulin inhibitor MMAE and a linker SMCC to make antibody drug conjugate. | Inquiry | |
| BADC-00857 | MC-Val-Cit-PAB-vinblastine | 2055896-92-7 |
| MC-Val-Cit-PAB-vinblastine is a drug-linker conjugate for ADC with potent antitumor activity by using vinblastine (an microtubule protein inhibitor), linked via the ADC linker MC-Val-Cit-PAB. | Inquiry | |
| BADC-00860 | Mal-PEG2-VCP-Eribulin | 2130869-18-8 |
| Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin. Eribulin is a mechanistically unique microtubule inhibitor for cancer. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates. | Inquiry | |
| BADC-00863 | DBCO-PEG4-Val-Cit-PAB-MMAF | 2244602-23-9 |
| DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). | Inquiry | |
| BADC-00864 | SC-VC-PAB-MMAE | 2259318-46-0 |
| SC-VC-PAB-MMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the cleavable linker SC-VC-PAB. | Inquiry | |
| BADC-00865 | Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA | 2259318-49-3 |
| Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin SA, linked via Mal-PEG4-VC-PAB-DMEA-Seco. | Inquiry | |
| BADC-00866 | Mal-Phe-C4-VC-PAB-MMAE | 2259318-51-7 |
| Mal-Phe-C4-VC-PAB-MMAE is made by MMAE conjugated to Mal-Phe-C4-VC-PAB linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. | Inquiry | |
| BADC-00868 | DBCO-(PEG2-VC-PAB-MMAE)2 | 2259318-55-1 |
| DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate. | Inquiry | |
| BADC-00869 | AcLysValCit-PABC-DMAE-SW-163D | 2411007-69-5 |
| AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugates for ADC which consists of a natural bis-intercalator, SW-163D, conjugated via an AcLysValCitPABC-DMAE linker. | Inquiry | |
| BADC-00871 | Fmoc-Val-Cit-PAB-Duocarmycin TM | |
| Fmoc-Val-Cit-PAB-Duocarmycin TM is a drug-linker conjugate for ADC by using the antitumor antibiotic, Duocarmycin TM, linked via Fmoc-Val-Cit-PAB. | Inquiry | |
| BADC-00799 | Streptonigrin | 3930-19-6 |
| Bruneomycin is a benzoquinone antibiotic produced by Auiw-myces albus van bruneomycini and Act. echinatus. It has anti-gram-positive bacteria, negative bacteria, and mycobacterial activity. It has inhibitory effect on lymphosarcoma Lio-1, lymphocytic leukemia NK/L1 and L-5178, Ehrlich ascites carcinoma, sarcoma-180, and has inhibitory effect on sarcoma-37 invalid. | Inquiry | |
| BADC-00357 | Ansamitocin P-3 | 66584-72-3 |
| It is produced by the strain of Nocardia sp. C-15003(N-1). It has the function of anti-tumor, anti-plant pathogenic fungi, skin fungi and protozoa, and has no antibacterial activity. | Inquiry | |
| BADC-01385 | DC10SMe | |
| DC10SMe is a DNA alkylating agent useful in the synthesis of antibody drug conjugates (ADCs). DC10SMe has IC50 values of 15 pM, 12 pM and 12 pM against Ramos, Namalwa and HL60/s cancer cells, respectively. | Inquiry | |
| BADC-01401 | DGN462 | 1394079-41-4 |
| DGN462 is a potent DNA alkylating agent with antitumor activity, such as against acute myeloid leukemia (AML). DGN462 can be used as an ADC toxin molecule to synthesize ADC. | Inquiry | |
| BADC-01441 | sulfo-DGN462 sodium | 1401203-09-5 |
| sulfo-DGN46 sodium can be degraded to DGN462 in culture medium and plasma. DGN462 is a potent DNA alkylating agent with antitumor activity, such as against acute myeloid leukemia (AML). | Inquiry | |
| BADC-01389 | PROTAC BRD4 Degrader-11 | |
| PROTAC BRD4 Degrader-11 is a PROTAC linked by ligands for von Hippel-Lindau and BRD4. It is conjugated with STEAP1 and CLL1 antibodies to degrade BRD4 protein in PC3 prostate cancer cells with DC50s of 0.23 nM and 0.38 nM, respectively. | Inquiry | |
| BADC-01386 | PROTAC BRD4 Degrader-9 | 2417370-42-2 |
| PROTAC BRD4 Degrader-9 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. It can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50 values of 0.86 nM and 7.6 nM, respectively. | Inquiry | |
| BADC-01388 | PROTAC BRD4 Degrader-10 | 2417370-49-9 |
| PROTAC BRD4 Degrader-10, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50s of 1.3 and 18 nM, respectively. | Inquiry | |
| BADC-01390 | PROTAC BRD4 Degrader-13 | 2417370-71-7 |
| PROTAC BRD4 Degrader-13, a PROTAC connected by ligands for von Hippel-Lindau and BRD4, can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with DC50s of 0.025 and 6.0 nM, respectively. | Inquiry |
